Skip to main content
Erschienen in: Acta Neurologica Belgica 4/2020

18.06.2020 | Letter to the Editor

A rare case of Opsoclonus-Myoclonus associated with SCLC

verfasst von: M. Lebeer, M. Montagna, S. Coito, T. Reynders, J. Raskin

Erschienen in: Acta Neurologica Belgica | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Excerpt

We report a case of a patient with a newly diagnosed small-cell lung cancer (SCLC), with paraneoplastic Opsoclonus-Myoclonus Syndrome (p-OMS) as the presenting symptom. Patients with OMS may have very debilitating symptoms, despite an albeit limited tumor load. Furthermore, OMS may be refractory to treatment, even in case of primary tumor response. Hence it represents a real challenge for the clinician, and a multidisciplinary approach (neurologist–oncologist) is recommended. …
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Oh S-SY, Kim J-S, Dieterich M et al (2019) Update on opsoclonus-myoclonus syndrome in adults. J Neurol 266:1541–1548CrossRef Oh S-SY, Kim J-S, Dieterich M et al (2019) Update on opsoclonus-myoclonus syndrome in adults. J Neurol 266:1541–1548CrossRef
2.
Zurück zum Zitat Wong AM, Mussalam S, Tomlinson RD et al (2001) Opsoclonus in three dimensions: oculographic, neuropathologic and modelling correlates. J Neurol Sci 189:71–81CrossRef Wong AM, Mussalam S, Tomlinson RD et al (2001) Opsoclonus in three dimensions: oculographic, neuropathologic and modelling correlates. J Neurol Sci 189:71–81CrossRef
3.
Zurück zum Zitat Armangué T, Sabater L, Torres-Vega E et al (2016) Clinical and immunological features of opsoclonus-myoclonus syndrome in the era of neuronal cell surface antibodies. JAMA Neurol 73(4):417–424CrossRef Armangué T, Sabater L, Torres-Vega E et al (2016) Clinical and immunological features of opsoclonus-myoclonus syndrome in the era of neuronal cell surface antibodies. JAMA Neurol 73(4):417–424CrossRef
4.
Zurück zum Zitat Bataller L, GrausF SA et al (2001) Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus–myoclonus. Brain 124(2):437–443CrossRef Bataller L, GrausF SA et al (2001) Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus–myoclonus. Brain 124(2):437–443CrossRef
5.
Zurück zum Zitat Horn L, Mansfield A, Mok T et al (2018) First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer (IMPOWER 133). N Engl J Med 379:2220–2229CrossRef Horn L, Mansfield A, Mok T et al (2018) First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer (IMPOWER 133). N Engl J Med 379:2220–2229CrossRef
6.
Zurück zum Zitat Paz-Ares L, Dvorkin M, Chen Y et al (2019) Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small–cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase 3 trial. Lancet 394(10212):1929–1939CrossRef Paz-Ares L, Dvorkin M, Chen Y et al (2019) Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small–cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase 3 trial. Lancet 394(10212):1929–1939CrossRef
7.
Zurück zum Zitat Graus F, Dalmau J (2019) Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol 16(9):535–548CrossRef Graus F, Dalmau J (2019) Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol 16(9):535–548CrossRef
8.
Zurück zum Zitat de Alarcon PA, Matthay KK, London WB et al (2018) Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. Lancet Child Adolesc 2:25–34CrossRef de Alarcon PA, Matthay KK, London WB et al (2018) Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. Lancet Child Adolesc 2:25–34CrossRef
9.
Zurück zum Zitat Rosenfeld M, Dalmau J (2013) Diagnosis and management of paraneoplastic neurologic disorders. Curr Treat Options Oncol 14:4CrossRef Rosenfeld M, Dalmau J (2013) Diagnosis and management of paraneoplastic neurologic disorders. Curr Treat Options Oncol 14:4CrossRef
10.
Zurück zum Zitat Shams’ili S, de Beukelaar J, Gratama JW et al (2006) An uncontrolled trial of Rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol 253:16CrossRef Shams’ili S, de Beukelaar J, Gratama JW et al (2006) An uncontrolled trial of Rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol 253:16CrossRef
11.
Zurück zum Zitat Pranzatelli MR, Tate ED, Travelstead AL et al (2006) Rituximab (anti-CD20) adjunctive therapy for opsoclonus–myoclonus syndrome. J Pediatr Hematol Oncol 28:585–593CrossRef Pranzatelli MR, Tate ED, Travelstead AL et al (2006) Rituximab (anti-CD20) adjunctive therapy for opsoclonus–myoclonus syndrome. J Pediatr Hematol Oncol 28:585–593CrossRef
Metadaten
Titel
A rare case of Opsoclonus-Myoclonus associated with SCLC
verfasst von
M. Lebeer
M. Montagna
S. Coito
T. Reynders
J. Raskin
Publikationsdatum
18.06.2020
Verlag
Springer International Publishing
Erschienen in
Acta Neurologica Belgica / Ausgabe 4/2020
Print ISSN: 0300-9009
Elektronische ISSN: 2240-2993
DOI
https://doi.org/10.1007/s13760-020-01402-6

Weitere Artikel der Ausgabe 4/2020

Acta Neurologica Belgica 4/2020 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.